Skip to main content
SpringerLink
Log in

Procainamide, Quinidine, Disopyramide, Cibenzoline, Pirmenol — Efficacy in the Treatment of Ventricular Arrhythmias: Current Status and Controversies

  • Chapter
Cardiac Arrhythmias: New Therapeutic Drugs and Devices

Part of the book series: Developments in Cardiovascular Medicine ((DICM,volume 47))

  • 41 Accesses

Abstract

In the review of the Type IA antiarrhythmic drugs, I will focus on the present knowledge regarding relative efficacy and toxicity in treating ventricular rhythm disturbances, and highlight a few areas of recent investigational interest including the antiarrhythmic efficacy of NAPA, bioavailability of sustained release preparations, as well as the issue of “proarrhythmia” with this group of medications. The assets and liabilities of the present classification system of antiarrhythmic agents has already been reviewed in this symposium. Suffice it to say that these drugs share certain electrophysiologic properties including their ability to decrease dV/dT of phase 0, producing conduction slowing, prolonging action potential duration and refractoriness, depressing membrane excitability, membrane responsiveness, and automaticity in normal Purkinje fibers.1 The current status of cibenzoline and pirmenol, two investigational agents for the treatment of ventricular rhythm disturbances, are also reviewed. Both these drugs share many electrophysiologic properties with the Type IA drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Pratt CM, Luck JC, Mann DE, Wyndham CRC: Investigational antiarrhythmic drugs for the treatment of ventricular rhythm disturbances. Cardiol Clin 2:35, 1984

    PubMed  CAS  Google Scholar 

  2. Berry K, Garlett E, Bellet S, Gefter W: Use of pronestyl in the treatment of ectopic rhythms. Am J Med 27:431, 1951

    Article  Google Scholar 

  3. Karlsson E: Procainamide and Phenytoin — comparative study of their antiarrhythmic effects at apparent therapeutic plasma levels. Br Heart J 37:731, 1975

    Article  PubMed  CAS  Google Scholar 

  4. Koch-Weser J, Klein S: Procainamide dosage schedules, plasma concentrations, and clinical effects. JAMA 215:1454, 1971

    CAS  Google Scholar 

  5. Winkle R, Gradman A, Fitzgerald J, Bell P: Antiarrhythmic drug effect assessed from ventricular arrhythmia reduction in ambulatory electrocardiogram and treadmill tests: comparison of propranolol, procainamide and quinidine. Am J Cardiol 42:473, 1978

    Article  PubMed  CAS  Google Scholar 

  6. Myerburg R, Kassler K, Keim I, Pefkaros K, Condi C, Cooper D, Castellanos A: Relationship between plasma levels of procainamide, suppression of premature ventricular complexes, and prevention of recurrent ventricular tachycardia. Circulation 64:280, 1981.

    Article  PubMed  CAS  Google Scholar 

  7. Buxton A, Roxman H, Marchonski F, Josephson M: Electropharmacology of nonsustained ventricular tachycardia: Effects of Class I antiarrhythmic agents, verapamil and propranolol. Am J Cardiol 53:738, 1984

    Article  PubMed  CAS  Google Scholar 

  8. Greenspan A, Horowitz L, Spielman S, Josephson F: Large dose procainamide therapy for ventricular tachyarrhythmia. Am J Cardiol 46:453, 1980

    Article  PubMed  CAS  Google Scholar 

  9. Waxman H, Buxton A, Sadowski L, Josephson M: The response to procainamide during electrophysiologic study for sustained ventricular tachyarrhythmias predicts the response to other medications. Circulation 67:30, 1983

    Article  PubMed  CAS  Google Scholar 

  10. Myerberg R, Condi C, Sheps D, Appel R, Kiem I, Sung R, Castelanos A: Antiarrhythmic drug therapy in survivors of prehospital cardiac arrest: Comparison of effects of chronic ventricular arrhythmias and recurrent cardiac arrest. Circulation 59:855, 1979

    Google Scholar 

  11. Vlasses P, Rocci M, Porini K, Greenspon A, Furguson R: Immediate-release and sustained-release procainamide: Bioavailability at steady state in cardiac patients. Ann Intern Med 98:613, 1983

    PubMed  CAS  Google Scholar 

  12. Giardiana E, Fenster P, Bigger JT, Mayersohn M, Perrier D, Marcus F: Efficacy, plasma concentration and adverse effects of a new sustained release procainamide preparation. Am J Cardiol 46:855, 1980

    Article  Google Scholar 

  13. Hore P, Bones P, Rolinson T, Ikram H: A pharmacokinetic comparison of two sustained-release oral procainamide preparations. Br J Clin Pharmacol 8:267, 1979

    PubMed  CAS  Google Scholar 

  14. Bauer G, Mitchell A, Bates F, Heloestrand K: The assessment of an antiarrhythmic agent, sustained-release procainamide, with the aid of Holter monitoring. Med J Aust 2:733, 1977

    PubMed  CAS  Google Scholar 

  15. Winkle R, Jailon P, Kates R, Peters F: Clinical pharmacology and antiarrhythmic efficacy of N-acetylprocainamide. Am J Cardiol 47:123, 1981

    Article  PubMed  CAS  Google Scholar 

  16. Roden D, Reele S, Higgins S, Wilkinson G, Smith R, Oates J, Woosley R: Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: Comparison with procainamide. Am J Cardiol 46:463, 1980

    Article  PubMed  CAS  Google Scholar 

  17. Jailon P, Rubenson D, Peters F, Mason J, Winkle R: Electrophysiologic effects of N-acetylprocainamide in human beings. Am J Cardiol 47:134, 1981.

    Article  Google Scholar 

  18. Sung R, Juma Z, Saksena S: Electrophysiologic properties and antiarrhythmic mechanisms of intravenous N-acetylprocainamide in patients with ventricular disarrhythmias. Am Heart J 105:811, 1983

    Article  PubMed  CAS  Google Scholar 

  19. Selzer A: Quinidine in perspective: “The rise and fall of quinidine.” Heart Lung 11:20, 1982

    PubMed  CAS  Google Scholar 

  20. Hodges M, Salerno D, Granrud G, and the Flecainide-Quinidine Research Group: Flecainide versus quinidine: Results of a multicenter trial. Am J Cardiol 53:66B, 1984

    Google Scholar 

  21. Flecainide-Quinidine Research Group: Flecainide versus quinidine for treatment of chronic ventricular arrhythmias in a multi-center clinical trial. Circulation 67:1117, 1983

    Article  Google Scholar 

  22. Sami M, Harrison D, Kramer H, Houston N, Shimasaki C, DeBusk R: Anti arrhythmic efficacy of encainide and quinidine: Validation of a model for drug assessment. Am J Cardiol 46:147, 1981

    Article  Google Scholar 

  23. Salerno D, Hodges M, Granrud G, Sharkey P: Comparison of flecainide with quinidine for suppression of chronic stable ventricular ectopic depolarizations. Ann Intern Med 98:455, 1983

    PubMed  CAS  Google Scholar 

  24. DiMarco J, Garan H, Ruskin J: Quinidine for ventricular arrhythmias: value of electrophysiologic testing. Am J Cardiol 51:90, 1983

    Article  PubMed  CAS  Google Scholar 

  25. Taggart W, Holyoak W: Steady-state bioavailability of two sustained-release quinidine preparations: quinidine gluconate versus quinidine sulfate. Clin Ther 5:357, 1983

    PubMed  CAS  Google Scholar 

  26. Meyer M, Straughn A, Lieberman P, Jacob J: Serious bioavailability problems with a generic prolonged-release quinidine gluconate product. J Clin Pharmacol 22:131, 1982

    PubMed  CAS  Google Scholar 

  27. Morady F, Scheinman M, Desai J: Disopyramide. Ann Intern Med 96:337, 1982

    CAS  Google Scholar 

  28. Pratt C, Young J, Francis M, Taylor A, Norton H, English L, Mann D, Kopelen H, Quiñones M, Roberts R: Comparative effect of disopyramide and ethmozin in suppressing complex ventricular arrhythmias by use of a double-blind, placebo-controlled, longitudinal crossover design. Circulation 69:288, 1984

    Article  PubMed  CAS  Google Scholar 

  29. Kjekshus J, Bathen J, Orning 0, Storstin L: A double-blind crossover comparison of flecainide acetate and disopyramide phosphate in the treatment of ventricular premature complexes. Am J Cardiol 53:72B, 1984

    Google Scholar 

  30. Lerman B, Waxman H, Buxton A, Josephson M: Disopyramide: Evaluation of electrophysiologic effects and clinical efficacy in patients with sustained ventricular tachycardia or ventricular fibrillation. Am J Cardiol 51:759, 1983

    Article  PubMed  CAS  Google Scholar 

  31. Fechter P, Ha H, Follath F, Nager F: The antiarrhythmic effects of controlled release disopyramide phosphate and long acting propranolol in patients with ventricular arrhythmias. Eur J Clin Pharmacol 25:729, 1983

    Article  PubMed  CAS  Google Scholar 

  32. Zema M: Serum drug concentrations and adverse effects in cardiac patients after administration of a new controlled-release disopyramide prepara tion. Ther Drug Monit 6:192, 1984

    Article  PubMed  CAS  Google Scholar 

  33. Nauta I, Van de Calseyde J, Hertzberger D: Plasma levels of disopyramide after administration of conventional capsules of sustained-release tablets. Curr Med Res Opin 8:582, 1983

    Article  PubMed  CAS  Google Scholar 

  34. Podrid P, Schoeneberger A, Lown B: Congestive heart failure caused by oral disopyramide. N Eng J Med 302:614, 1980

    Article  CAS  Google Scholar 

  35. Desai J, Scheinman M, Hirschfeld D, Zelis R, Peters R: Cardiovascular collapse associated with disopyramide therapy. Chest 79:545, 1981

    Article  PubMed  CAS  Google Scholar 

  36. Kowey P, Friedman P, Podrid P, Zielong J, Lown B, Woinn J, Hallman B: Use of radionuclide ventriculography for assessment of changes in myo cardial performance using disopyramide phosphate.Am Heart J 104:769, 1982

    Article  PubMed  CAS  Google Scholar 

  37. Greene A, Iskandrin A, Hokki A, Kane S, Segeal B: Effective role of disopyramide therapy on left ventricular function. Chest 83:480, 1983

    Article  PubMed  CAS  Google Scholar 

  38. Wisenberg G, Zawadowski G, Gebhardt B, Prato F, Goddard M, Nichol P, Rechnitzer P, Gryfe-Becker B: Effects of ventricular function of disopyramide, procainamide and quinidine as determined by radionuclide angiography. Am J Cardio 53:1292, 1984

    Article  CAS  Google Scholar 

  39. Delibat V, Podrid P, Laun B, Cohen B, Grabois T: Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs. Circulation 65:886, 1982

    Article  Google Scholar 

  40. Bauman J, Bauernfeind R, Hoff J, Strasberg B, Swiryn S, Rosen K: Torsade de pointes due to quinidine: Observations in 31 patients. Am Heart J 107:425, 1984

    Article  PubMed  CAS  Google Scholar 

  41. Pratt C, Francis M, Luck J, Wyndham C, Miller R, Quinones M: Analysis of ambulatory electrocardiograms in 15 patients during spontaneous ventri cular fibrillation with special reference to preceding arrhythmic events. JACC 2:789, 1983.

    PubMed  CAS  Google Scholar 

  42. Denes P, Gabster A, Huang S: Clinical, electrocardiographic and follow-up observations in patients having ventricular fibrillation during Holter monitoring. Am J Cardiol 48:9, 1981

    Article  PubMed  CAS  Google Scholar 

  43. Chow M, Piergies A, Bowsher D, Ruffi J, Krichner W, Ruo T, Assada A, Kawana J, Adkinson A: Torsade de pointes induced by N-acetylprocainamide. JACC 4:621, 1984

    PubMed  CAS  Google Scholar 

  44. Olshanski B, Martins J, Clint S: N-acetylprocainamide causing torsade de pointes. Am J Cardiol 50:1439, 1982

    Article  Google Scholar 

  45. Commerford P, Beck W: Ventricular tachycardia with torsade de pointes morphology induced by oral disopyramide. S Afr Med J 58:447, 1980

    PubMed  CAS  Google Scholar 

  46. Chia B: Disopyramide induced atypical ventricular tachycardia. Aust NZ J Med 10:665, 1980

    Article  CAS  Google Scholar 

  47. Lowe K, Gantz K, Stetson P, Lucchesi B, Pitt B: Disopyramide-induced ventricular tachycardia. Arch Intern Med 140:413, 1980

    Article  Google Scholar 

  48. Croft C, Kennelly B: Ventricular tachyarrhythmias induced by disopyramide and other similar anti-arrhythmic drugs. S Afr Med J 59:871, 1981

    PubMed  CAS  Google Scholar 

  49. Wald R, Waxman M, Colman J: Torsade de pointes ventricular tachycardia: A complication of disopyramide shared with quinidine. J Electrocardiol 14:301, 1981

    Article  PubMed  CAS  Google Scholar 

  50. May G, Ederlein K, Furberg C, Passamani E, DeMets D: Secondary prevention after myocardial infarction: A review of long-term trials. Prog Cardiovasc Dis 4:331, 1982

    Article  Google Scholar 

  51. Furberg C: Effective antiarrhythmic drugs on mortality after myocardial infarction. Am J Cardiol 52:32C, 1983

    Google Scholar 

  52. Browne K, Prytowski E, Zipes D, Chilson D, Heger J: Clinical efficacy and electrophysiologic effects of cibenzoline therapy in patients with ventricular arrhythmias. JACC 3:857, 1984

    PubMed  CAS  Google Scholar 

  53. Kostis J, Krieger S, Morayra A, Cosgrove N: Cibenzoline for treatment of ventricular arrhythmias: A double-blind placebo-controlled study. JACC 4:372, 1984.

    PubMed  CAS  Google Scholar 

  54. Coceo G, Strozzi C, Pansini R, Rochat N, Boulgarelli R, Padula A, Sfrasi C, Yassini A: Antiarrhythmic use of cibenzoline, a new Class I antiarrhythmic agent with Class III and IV properties in patients with recurrent ventricular tachycardia. Eur Heart J 5:108, 1984

    Google Scholar 

  55. Kushner M, Magirose, Peters R, Carliner N, Plotnick G, Fisher M: The electrophysiologic effects of oral cibenzoline. J Electrocard 17:15, 1984

    Article  CAS  Google Scholar 

  56. Canal M, Flouvat B, Trenblay D, DuFour A: Pharmacokinetics in man of a new antiarrhythmic drug, cibenzoline. Eur J Pharmacol 24:509, 1983

    Article  CAS  Google Scholar 

  57. Brazzell R, Aogaichi K, Heger J, Somberg J, Carliner N, Morganroth J: Cibenzoline plasma concentration and antiarrhythmic effect. Clin Pharmacol Ther 35:307, 1984

    Article  PubMed  CAS  Google Scholar 

  58. Hammil S, Shand D, Rutledge P, Hindman M, Baker J, Pritchett E: Pirmenol, a new antiarrhythmic agent: Initial study of efficacy, safety and pharmacokinetics. Circulation 65:369, 1982

    Article  Google Scholar 

  59. Anderson K, Lutz J, Nappi J: Pirmenol for control of ventricular arrhythmias: oral dose-ranging and short-term maintenance study. Am J Cardiol 53:522, 1984

    Article  PubMed  CAS  Google Scholar 

  60. Anderson J, Lutz J, Sanders S, Nappi J: Efficacy of intravenous pirmenol hydrochloride for treatment of ventricular arrhythmias: A controlled comparison with lidocaine. J Cardiovasc Pharmacol 5:213, 1983.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Craig M. Pratt M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Likoff Cardiovascular Institute of Hahnemann Medical College and Hospital, USA

    Joel Morganroth

  2. School of Veterinary Medicine, University of Pennsylvania, USA

    E. Neil Moore

Rights and permissions

Reprints and permissions

Copyright information

© 1985 Martinus Nijhoff Publishing, Boston

About this chapter

Cite this chapter

Pratt, C.M. (1985). Procainamide, Quinidine, Disopyramide, Cibenzoline, Pirmenol — Efficacy in the Treatment of Ventricular Arrhythmias: Current Status and Controversies. In: Morganroth, J., Moore, E.N. (eds) Cardiac Arrhythmias: New Therapeutic Drugs and Devices. Developments in Cardiovascular Medicine, vol 47. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2595-6_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-2595-6_5

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-9626-3

  • Online ISBN: 978-1-4613-2595-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation